Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
12.58
-0.52 (-3.97%)
At close: Jul 22, 2026, 4:00 PM EDT
12.38
-0.20 (-1.59%)
Pre-market: Jul 23, 2026, 7:36 AM EDT
Climb Bio Market Cap
Climb Bio has a market cap or net worth of $720.34 million as of July 23, 2026. Its market cap has increased by 656.01% in one year.
Market Cap
720.34M
Enterprise Value
574.51M
1-Year Change
656.01%
Ranking
Category
Stock Price
$12.58
ChartMarket Cap Chart
Since August 10, 2021, Climb Bio's market cap has increased from $403.20M to $720.34M, an increase of 78.66%. That is a compound annual growth rate of 12.44%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 22, 2026 | 720.34M | 277.18% |
| Dec 31, 2025 | 190.98M | 57.83% |
| Dec 31, 2024 | 121.00M | 62.54% |
| Dec 29, 2023 | 74.45M | -23.65% |
| Dec 30, 2022 | 97.50M | -64.90% |
| Dec 31, 2021 | 277.76M | -31.11% |
| Aug 10, 2021 | 403.20M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Aura Biosciences | 775.40M |
| Bright Minds Biosciences | 765.45M |
| Monopar Therapeutics | 760.78M |
| Design Therapeutics | 753.23M |
| Candel Therapeutics | 748.82M |
| CytomX Therapeutics | 744.54M |
| Zevra Therapeutics | 735.98M |
| Faeth Therapeutics | 731.34M |